Clinical trials: Peripheral T Cell Lymphoma
Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade
Tandem Auto-Allo Transplant for Lymphoma
Relapse remains a principle cause of treatment failure for patients with aggressive lymphoma after autologous transplantation. Non-myeloablative allogeneic transplantation allows patients to receive an infusion of donor cells in…
- Conditions
- Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma, Mantle-Cell Lymphoma
- Trial name
- NCT01181271
- Testing
- Busulfan (conditioning for AUTO transplant), Etoposide (conditioning for AUTO transplant), Cyclophosphamide (conditioning for AUTO transplant)
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
Adult T Cell Leukemia, Adult T Cell Lymphoma
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
This clinical trial will be a multicenter phase II fixed-dose trial in which a minimum of 10 patients with immunophenotypically confirmed ATL with at least 50% of the blasts expressing CD25 as measured by flow cytometry at…
- Trial name
- NCT01378871
- Testing
- IMTOX-25
- Where
- 7 sites in United States
- Volunteers
- 1 people
- Sponsor
- Amit Verma
Extranodal Natural Killer/T-Cell Lymphoma
A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)
This is a multicenter, single-arm, phase II study to evaluate the efficacy and safety of CS1001 monotherapy for Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma (ENKTL)
- Trial name
- NCT03595657
- Testing
- CS1001
- Where
- 17 sites in China
- Volunteers
- 80 people
- Sponsor
- CStone Pharmaceuticals
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
Lymphoma
Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin and bexarotene, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00255801
- Testing
- Targretin® (bexarotene), pegylated liposomal doxorubicin hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides
The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.
- Trial name
- SOLAR (NCT03713320)
- Testing
- Cobomarsen, Vorinostat
- Where
- 43 sites in United States, Australia and 6 more
- Volunteers
- 37 people
- Sponsor
- miRagen Therapeutics, Inc.
Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
Background: Improved treatments for a variety of treatment-resistant, TNFRSF8 (CD30)-expressing malignancies including Hodgkin lymphoma, anaplastic large cell lymphoma, and other CD30- expressing lymphomas are needed.
- Conditions
- Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Extranodal NK-T-Cell
- Trial name
- NCT03049449
- Testing
- Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
This phase II trial studies how well giving fludarabine phosphate, cyclophosphamide, tacrolimus, mycophenolate mofetil and total-body irradiation together with a donor bone marrow transplant works in treating patients with…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00049504
- Testing
- cyclophosphamide, fludarabine phosphate, tacrolimus
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
This phase I/II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of…
- Conditions
- Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma
- Trial name
- NCT03598998
- Testing
- Pembrolizumab, Pralatrexate
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- City of Hope Medical Center
Lymphoma, T-Cell, Peripheral
Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
This is a multicenter, single-arm, open label, study consisting of two cohorts. Cohort 2 explores the combination of copanlisib and pembrolizumab in patients with relapsed or refractory NKTCL, who have received at least 1 prior…
- Trial name
- NCT02535247
- Testing
- MK-3475, Copanlisib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Fox Chase Cancer Center
Anemia, Leukemia
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00416624
- Testing
- darbepoetin alfa, epoetin alfa, fatigue assessment and management
- Where
- United States
- Volunteers
- 239 people
- Sponsor
- Mayo Clinic
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
This study is for patients with lymphoproliferative malignancies that have progressed after receiving a previous treatment (relapsed) or are no longer responding to treatment (refractory).
- Conditions
- Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma
- Trial name
- NCT00481871
- Testing
- Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12
- Where
- 15 sites in United States
- Volunteers
- 119 people
- Sponsor
- Acrotech Biopharma Inc.
Lymphoma, Disorder Related to Bone Marrow Transplantation
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
The goal of this clinical research study is to see if receiving a transplant of blood stem cells (cells that can produce blood) or bone marrow from either a related donor (brother, sister or other relative) or an unrelated…
- Trial name
- NCT00506129
- Testing
- Fludarabine, Melphalan, Allogeneic Transplant
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Large-Cell, Ki-1, Lymphoma, T-Cell
UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas
This study will examine the effects of an experimental drug called UCN-01 (7-hydroxystaurosporine) on T-cell lymphomas. UCN-01 inhibits the growth of several different tumor cells, and, in laboratory studies, it has worked…
- Trial name
- NCT00082017
- Testing
- UCN-01 (7-hydroxystaurosporine)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
This study will enroll subjects with either Peripheral T-Cell Lymphoma (PTCL) or Cutaneous T-Cell Lymphoma(CTCL),including mycosis fungoides (MF) and Sezary Syndrome (SS), who have relapsed after achieving a complete response in…
- Trial name
- NCT01226472
- Testing
- KW-0761
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Kyowa Kirin Co., Ltd.
B-Cell Prolymphocytic Leukemia, Hypodiploidy
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
This phase II trial studies autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in treating patients with high-risk Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, or chronic…
- Conditions
- B-Cell Prolymphocytic Leukemia, Hypodiploidy, Loss of Chromosome 17p, Plasma Cell Leukemia
- Trial name
- NCT01008462
- Testing
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fred Hutchinson Cancer Center
Peripheral T-cell Lymphoma
Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients
Pilot clinical trial - Phase 2a, multicenter, single arm, open label trial - to evaluate efficacy and safety of concomitant combination treatment with Gemcitabine and Romidepsin (GEMRO) regimen as salvage treatment in…
- Trial name
- FIL_GEMRO (NCT01822886)
- Testing
- Romidepsin + Gemcitabine
- Where
- 4 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Leukemia
Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- LAL0904 (NCT00458848)
- Testing
- asparaginase, daunorubicin hydrochloride, etoposide
- Where
- 66 sites in Italy
- Volunteers
- 470 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Peripheral T-Cell Lymphoma
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
The standard treatment for PTCL is CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy.
- Trial name
- NCT00337987
- Testing
- Ontak, CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Yale University
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma
RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Giving vaccine therapy after an autologous stem cell transplant may kill any cancer cells that remain after transplant.
- Conditions
- Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Small Intestine Cancer
- Trial name
- NCT00569309
- Testing
- Streptococcus pneumoniae, laboratory correlative studies, quality-of-life assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center